Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARVN NASDAQ:NRXP NASDAQ:STTK NASDAQ:ZSQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.56-0.3%$8.57$6.05▼$14.51$554.24M1.74765,055 shs570,958 shsNRXPNRx Pharmaceuticals$3.92-5.8%$3.67$1.62▼$5.05$150.71M2.19791,803 shs1.14 million shsSTTKShattuck Labs$6.88-5.2%$5.92$0.71▼$8.33$556.70M1.051.68 million shs1.03 million shsZSQRCoeptis Therapeutics$7.04-17.1%$11.56$6.94▼$21.41$436.65M-0.25765,853 shs611,553 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+1.66%+3.37%+15.77%-23.37%+10.27%NRXPNRx Pharmaceuticals+5.58%+1.71%+0.48%+84.89%+23.44%STTKShattuck Labs+0.28%+4.61%+58.52%+3.42%+840.41%ZSQRCoeptis Therapeutics-22.75%-19.75%-16.11%-21.75%+9.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARVNArvinas$8.56-0.3%$8.57$6.05▼$14.51$554.24M1.74765,055 shs570,958 shsNRXPNRx Pharmaceuticals$3.92-5.8%$3.67$1.62▼$5.05$150.71M2.19791,803 shs1.14 million shsSTTKShattuck Labs$6.88-5.2%$5.92$0.71▼$8.33$556.70M1.051.68 million shs1.03 million shsZSQRCoeptis Therapeutics$7.04-17.1%$11.56$6.94▼$21.41$436.65M-0.25765,853 shs611,553 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARVNArvinas+1.66%+3.37%+15.77%-23.37%+10.27%NRXPNRx Pharmaceuticals+5.58%+1.71%+0.48%+84.89%+23.44%STTKShattuck Labs+0.28%+4.61%+58.52%+3.42%+840.41%ZSQRCoeptis Therapeutics-22.75%-19.75%-16.11%-21.75%+9.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARVNArvinas 2.46Hold$15.4280.10% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25875.77% UpsideSTTKShattuck Labs 2.80Moderate Buy$11.0059.88% UpsideZSQRCoeptis Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest NRXP, ZSQR, ARVN, and STTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/16/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/8/2026STTKShattuck Labs Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $17.006/8/2026STTKShattuck Labs HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.006/5/2026STTKShattuck Labs Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform$7.006/5/2026STTKShattuck Labs CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$7.006/4/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/3/2026ARVNArvinas StephensSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$18.006/2/2026STTKShattuck Labs Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026ARVNArvinas Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/19/2026ARVNArvinas Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARVNArvinas$262.60M2.10N/AN/A$6.76 per share1.27NRXPNRx Pharmaceuticals$1.23M115.46N/AN/A($0.54) per share-7.26STTKShattuck Labs$1M527.56N/AN/A$1.30 per share5.29ZSQRCoeptis Therapeutics$1.36M266.23N/AN/A$2.63 per share2.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARVNArvinas-$80.80M-$3.32N/AN/AN/A-247.54%-44.38%-28.38%8/5/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.64N/AN/AN/A-202.92%8/17/2026 (Estimated)STTKShattuck Labs-$48.81M-$0.63N/AN/AN/AN/A-60.73%-55.75%8/13/2026 (Estimated)ZSQRCoeptis Therapeutics-$11.92M-$2.52N/AN/AN/A-810.04%-92.29%-73.52%N/ALatest NRXP, ZSQR, ARVN, and STTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026ARVNArvinas-$0.24N/AN/AN/A$61.37 millionN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/14/2026Q1 2026ZSQRCoeptis TherapeuticsN/A-$0.65N/A-$0.65N/A$0.11 million5/11/2026Q1 2026ARVNArvinas-$0.95-$0.90+$0.05-$0.90$16.61 million$15.60 million5/7/2026Q1 2026STTKShattuck Labs-$0.14-$0.13+$0.01-$0.13N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARVNArvinasN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ASTTKShattuck LabsN/AN/AN/AN/AN/AZSQRCoeptis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARVNArvinasN/A5.445.44NRXPNRx PharmaceuticalsN/A0.290.29STTKShattuck LabsN/A22.0722.06ZSQRCoeptis Therapeutics0.013.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARVNArvinas95.19%NRXPNRx Pharmaceuticals4.27%STTKShattuck Labs58.74%ZSQRCoeptis Therapeutics13.88%Insider OwnershipCompanyInsider OwnershipARVNArvinas7.30%NRXPNRx Pharmaceuticals6.40%STTKShattuck Labs8.79%ZSQRCoeptis Therapeutics24.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARVNArvinas42064.52 million59.81 millionOptionableNRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableSTTKShattuck Labs10076.68 million69.94 millionOptionableZSQRCoeptis Therapeutics251.43 million38.96 millionNot OptionableNRXP, ZSQR, ARVN, and STTK HeadlinesRecent News About These CompaniesCoeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) Short Interest UpdateJuly 2, 2026 | americanbankingnews.comZ Squared Inc. Appoints Jeffrey Harris as Chief Technology OfficerJune 30, 2026 | prnewswire.comZ Squared Raises Approximately $15.3 Million in Non-Debt Capital to Advance AI Infrastructure StrategyJune 29, 2026 | prnewswire.comRussell Indexes Add Z Squared Inc. to Russell 2000® and Russell 3000®June 29, 2026 | prnewswire.comZ Squared, Inc. to Acquire Majority Interest in Paradox Data and Its Union County Campus, a Next-Generation Data Center Development Targeting Up to 150 MW of Firm PowerJune 25, 2026 | prnewswire.comZ Squared to Participate in Maxim Group's AI Data Center SummitJune 9, 2026 | prnewswire.comZ Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure BuildoutJune 4, 2026 | prnewswire.comZ Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® IndexesMay 27, 2026 | prnewswire.comVanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready PowerMay 26, 2026 | globenewswire.comZ Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference WorkloadsMay 19, 2026 | prnewswire.comZ Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory BoardMay 4, 2026 | prnewswire.comZ Squared to Acquire Skycore Digital, Adding 24 MW of Energized AI Infrastructure with Expansion Path to 42 MWApril 29, 2026 | prnewswire.comZ Squared, Inc. to Ring the Nasdaq Closing Bell in Celebration of Its Listing on the Nasdaq Global MarketApril 28, 2026 | prnewswire.comCoeptis Therapeutics Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 27, 2026 | finanznachrichten.deZ Squared Provides Additional Information on Previously Disclosed Pro Rata DistributionApril 27, 2026 | tmcnet.comCoeptis Therapeutics Receives Shareholder Approval Towards Z Squared MergerApril 27, 2026 | finanznachrichten.deZ Squared Inc.: Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 25, 2026 | finanznachrichten.deZ Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 24, 2026 | prnewswire.comCoeptis Therapeutics: Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 9, 2026 | finanznachrichten.deWhy Coeptis Therapeutics Holdings, Inc.’s (COEP) Stock Is Up 10.60%April 9, 2026 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeNRXP, ZSQR, ARVN, and STTK Company DescriptionsArvinas NASDAQ:ARVN$8.56 -0.03 (-0.35%) Closing price 04:00 PM EasternExtended Trading$8.43 -0.13 (-1.52%) As of 06:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.NRx Pharmaceuticals NASDAQ:NRXP$3.92 -0.24 (-5.77%) Closing price 04:00 PM EasternExtended Trading$3.95 +0.03 (+0.77%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.Shattuck Labs NASDAQ:STTK$6.88 -0.38 (-5.23%) Closing price 04:00 PM EasternExtended Trading$6.97 +0.09 (+1.37%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.Coeptis Therapeutics NASDAQ:ZSQR$7.04 -1.45 (-17.08%) As of 04:00 PM EasternCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
